优化儿童肾病综合征吗替麦考酚酸暴露以降低复发风险
该回顾性队列研究纳入89例接受吗替麦考酚酸治疗的儿童肾病综合征患者,评估MPA AUC0-12h与复发的关系。研究发现较低MPA AUC0-12h与复发强相关,ROC确定31.51 μg/h/mL为最佳风险参考值,维持该暴露水平可显著降低复发风险,治疗药物监测指导个体化给药至关重要。
要点
- MPA AUC0-12h较低与儿童肾病综合征复发强相关。
- ROC确定31.51 μg/h/mL为最佳风险参考值。
- 治疗药物监测指导MMF个体化给药对优化结局至关重要。
核心结论
- 维持MPA AUC0-12h ≥ 31.51 μg/h/mL可显著降低儿童肾病综合征复发风险。
- 基于治疗药物监测的个体化吗替麦考酚酯给药对优化结局至关重要。
研究设计与样本
- 回顾性队列研究,纳入89例接受MPA治疗的儿童肾病综合征患者。
- 采用二元逻辑回归评估复发影响因素,ROC曲线确定最佳截断阈值,Kaplan-Meier和Cox回归分析无复发生存。
主要发现
- 复发组MPA AUC0-12h为31.49 μg/h/mL,非复发组为36.48 μg/h/mL,差异有统计学意义(P < 0.001)。
- 逻辑回归证实MPA AUC0-12h为保护因素(OR = 0.93,95%CI:0.88-0.99)。
- ROC分析确定31.51 μg/h/mL为最佳风险参考值(敏感性=87.5%,特异性=51.02%)。
- Cox回归显示低于阈值暴露为独立复发风险(HR = 0.24,95%CI:0.14-0.43,P < 0.001)。
- 亚组分析在皮质类固醇反应、复发频率和利妥昔单抗使用中验证该风险参考值,但在局灶节段性肾小球硬化中未验证。
关键数值与推荐
- MPA AUC0-12h最佳风险参考值为31.51 μg/h/mL(敏感性87.5%,特异性51.02%)。
- MPA AUC0-12h每增加1单位,复发风险降低(OR = 0.93,95%CI:0.88-0.99)。
- 低于阈值暴露的复发风险HR = 0.24(95%CI:0.14-0.43,P < 0.001)。
临床怎么用
- 对接受MMF治疗的儿童肾病综合征患者进行治疗药物监测,维持MPA AUC0-12h ≥ 31.51 μg/h/mL以降低复发风险。
- 根据MPA AUC0-12h结果个体化调整MMF剂量。
局限性
- 本研究为回顾性队列研究。
- 风险参考值在局灶节段性肾小球硬化亚组中未得到验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Mycophenolic acid (MPA) effectively reduces relapse in paediatric nephrotic syndrome (NS), yet its pharmacokinetic variability hinders optimal dosing. This study aimed to define risk reference values of MPA area under the concentration-time curve (AUC0-12h) for relapse prevention during maintenance therapy. METHODS: In this retrospective cohort study, 89 paediatric NS patients receiving MPA were enrolled. Factors influencing relapse were evaluated via binary logistic regression. Optimal cut-off threshold were determined using receiver operating characteristic (ROC) curves, while Kaplan-Meier and Cox regression analyses assessed relapse-free survival (RFS). RESULTS: Lower MPA AUC0-12h levels strongly correlated with relapse (relapse group: 31.49 vs. non-relapse: 36.48 μg/h/mL, P < 0.001). Logistic regression confirmed MPA AUC0-12h as a protective factor (odds ratio [OR] = 0.93, 95% confidence interval [CI]: 0.88-0.99). ROC analysis identified 31.51 μg/h/mL as the optimal risk reference value (sensitivity = 87.5%, specificity = 51.02%). Cox regression further demonstrated subthreshold exposure as an independent relapse risk (hazard ratio [HR] = 0.24, 95% CI: 0.14-0.43, P < 0.001). Subgroup analyses validated this risk reference value across corticosteroid response, relapse frequency and rituximab use, though not in focal segmental glomerulosclerosis. CONCLUSIONS: Maintaining MPA AUC0-12h ≥ 31.51 μg/h/mL significantly reduces relapse risk in paediatric NS. Individualized mycophenolate mofetil (MMF) dosing guided by therapeutic drug monitoring is critical for optimizing outcomes.
引用
- Cai Y, Liu B, Chen L, et al. Optimizing mycophenolic acid exposure for reduced relapse risk in paediatric nephrotic syndrome: An observational cohort study. Br J Clin Pharmacol. 2025. PMID: 41063552. doi:10.1002/bcp.70307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。